Intrahepatic Cholangiocarcinoma (I-CC) or Mixed Hepatocellular-Cholangiocarcinoma (HCC-CC) in Patients Undergoing Liver Transplantation (LT). A Spanish Case Control Multicenter Study

R. Charco, G. Sapisochin, C. Rodriguez-Lope, M. Gastaca, J. Ortiz de Urbina, R. Lopez-Andujar, F. Palacios, E. Ramos, J. Fabregat, J. Castroagudin, E. Varo, J. Pons, P. Parrilla, M. Gonzalez-Dieguez, M. Rodriguez, A. Otero, M. Vazquez, G. Zozaya, J. Herrero, G. Sanchez Antolin, B. Perez, R. Ciria, S. Rufián, Y. Fundora, J. Ferrón, A. Guiberteau, G. Blanco, M. Varona, M. Barrera, M. Suarez, J. Santoyo, J. Bruix

Hosital Universitario Vall d'Hebron, Barcelona, Spain
Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
Hospital Universitario de Cruces. Universidad del Pais Vasco, Bilbao, Spain
Hospital Universitario La Fe, Valencia, Spain
Hospital Universitraio de Bellvitge, L'Hospitalet de Llobregat, Spain
Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Hospital Virgen de la Arrixaca, Murcia, Spain
Hospital Central de Asturias, Oviedo, Spain
Hospital Universitario de A Coruña, La Coruña, Spain
Clinica Universitaria de Navarra, Pamplona, Spain
Hospital Rio Hortega, Valladolid, Spain
Hospital Universitario Reina Sofia, Córdoba, Spain
Hospital Universitraio Virgen de las Nieves, Granada, Spain
Hospital Universitario Infanta Cristina, Badajoz, Spain
Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
Hospital Carlos Haya, Malaga, Spain

Meeting: 2013 American Transplant Congress

Abstract number: A701

Aim: to evaluate the outcome of patients with HCC-CC or I-CC at explant pathology after LT for suspected HCC.

Methods:A case-control study 1:2. Study group(n=42) formed by patients with HCC-CC or I-CC in the pathology exam. Control group(n=84) formed by patients with HCC in the pathology exam, matched by number, nodule size and liver disease. The I-CC subgroup(27 patients with I-CC or separate I-CC and HCC vs. 54 controls) and HCC-CC subgroup(15 patients with HCC-CC vs. 30 controls) were also analyzed separately.

Results: No differences were found in age, sex, etiology, Child-Pugh, MELD, AFP, waiting time, and treatment before LT between groups. One, 3 and 5-year actuarial survival differed between study and control groups (83%, 70% and 60% vs. 99%, 94%, and 89%, respectively, p<0.001). Differences were found in 1, 3 and 5-year actuarial survival between the I-CC subgroup and their controls (78%, 66% and 51% vs. 100%, 98% and 93%, p<0.001) but no differences were observed between the HCC-CC subgroup and their controls.

Conclusions: Preoperative diagnosis of HCC-CC should not prompt the exclusion of these patients from transplantation.

To cite this abstract in AMA style:

Charco R, Sapisochin G, Rodriguez-Lope C, Gastaca M, Urbina JOrtizde, Lopez-Andujar R, Palacios F, Ramos E, Fabregat J, Castroagudin J, Varo E, Pons J, Parrilla P, Gonzalez-Dieguez M, Rodriguez M, Otero A, Vazquez M, Zozaya G, Herrero J, Antolin GSanchez, Perez B, Ciria R, Rufián S, Fundora Y, Ferrón J, Guiberteau A, Blanco G, Varona M, Barrera M, Suarez M, Santoyo J, Bruix J. Intrahepatic Cholangiocarcinoma (I-CC) or Mixed Hepatocellular-Cholangiocarcinoma (HCC-CC) in Patients Undergoing Liver Transplantation (LT). A Spanish Case Control Multicenter Study [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/intrahepatic-cholangiocarcinoma-i-cc-or-mixed-hepatocellular-cholangiocarcinoma-hcc-cc-in-patients-undergoing-liver-transplantation-lt-a-spanish-case-control-multicenter-study/. Accessed May 14, 2025.

« Back to 2013 American Transplant Congress